MK-2060
Sponsors
Merck Sharp & Dohme LLC
Conditions
End-Stage Kidney DiseaseEnd-Stage Kidney Disease (ESKD)End-Stage Renal DiseaseEnd-Stage Renal Disease (ESRD)HealthyKidney Failure, ChronicPrevention of arteriovenous graft thrombosisRenal Dialysis
Phase 1
Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)
CompletedNCT03873038
Start: 2019-04-29End: 2021-12-20Updated: 2024-06-06
MK-2060 and Clopidogrel Co-administration Safety and Tolerability Study in Participants With End-Stage Renal Disease (ESRD) (MK-2060-008)
CompletedNCT05335005
Start: 2022-05-30End: 2023-02-14Updated: 2024-10-17
A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011)
CompletedNCT05656040
Start: 2023-02-08End: 2024-08-12Updated: 2025-09-10
Single Dose Study of MK-2060 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Older Japanese Participants on Dialysis (MK-2060-012)
CompletedNCT05769595
Start: 2023-06-14End: 2024-02-15Updated: 2025-03-14
A Study of MK-2060 in Healthy Participants (MK-2060-016)
CompletedNCT06582602
Start: 2024-10-15End: 2025-04-18Updated: 2025-05-21
Single-Ascending Dose Study of MK-2060 in Healthy Chinese Male Adult Participants (MK-2060-009)
CompletedNCT06843993
Start: 2023-03-01End: 2023-10-27Updated: 2025-02-25
Phase 2
Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
CompletedNCT05027074
Start: 2021-09-17End: 2025-02-13Updated: 2026-02-11
A Randomized Parallel-group, Placebo-controlled, Double-blind, Eventdriven, Multi-center Phase 2 Clinical Outcome Trial of Prevention of Arteriovenous Graft Thrombosis and Safety of MK-2060 in Patients With End Stage Renal Disease Receiving Hemodialysis
CompletedCTIS2024-511055-17-00
Start: 2021-11-25End: 2025-02-11Target: 93Updated: 2024-10-25